A phase 1/2 study evaluating brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma after failure of frontline therapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Seattle Genetics

Protocol Number
SGN35-025

To Learn More Call
201-510-0910